C21 Investments Inc. CXXIF CXXI released its audited financial statements for its fiscal year ended January 31, 2023, revealing revenue of $28.9 million – down 12% compared to $33 million in FY 2022.
FY 2023 Financial Highlights
-
Gross profit was $13.4 million compared to $18.8 million in FY 2022.
-
Gross margin of 46.4% compared to 57% in FY 2022.
-
Net income was $293,211, a decrease of 97% compared to $10 million in FY 2022.
-
Adjusted EBITDA of $7.4 million, compared to $12.4 million in FY 2022.
-
Cash at the end of the year was $1.9 million
The British Columbia Securities Commission issued a cease trade order on June 6, 2023 in respect of the company's securities in connection with the delay in the company filing its audited consolidated financial statement for the year ended January 31, 2023, annual management's discussion and analysis for the same period and management certifications of annual filings. The company has provided notice to the British Columbia Securities Commission of the completion of the annual filings and has been informed that the CTO will be revoked June 15, 2023.
"We are pleased to announce the release of our audited year-end financial statements. We appreciate the patience of our shareholders during this delay while our tax provision changes for our previous fiscal year were corrected and restated," stated CEO and president, Sonny Newman.
Photo by Giorgio Trovato on Unsplash
Related News
C21 Investments Cancels Swell Earn-Out Shares
C21 Investments Q3 2023 Revenue Declines 9.2% YoY, What About Net Income?
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.